Table 1.

Patient information

Patient	Monoclonal protein	Number of prior lines of therapy*	CAR-BCMA T cells infused (per kg)	Myeloma response (duration in weeks; + means ongoing)†
1	κ light chain only	7	0.3 × 106	PR (2)
2	IgA-λ	10	0.3 × 106	SD (6)
3	κ light chain only	8	0.3 × 106	SD (6)
4	λ light chain only	7	1 × 106	SD (12)
5	IgG-κ	13	1 × 106	SD (4)
6	IgG-λ	11	1 × 106	SD (2)
7	IgG-λ	6	3 × 106	SD (7)
8	κ light chain only	8	3 × 106	VGPR (8)
9	κ light chain only	4	3 × 106	SD (16)
10	IgA-κ	3	9 × 106	Stringent CR (17)
11	IgG-λ	5	9 × 106	VGPR (26+)
12	IgA-λ	5	3 × 106	SD (2)

^*The number of prior lines of therapy was calculated by adding all discreet lines of therapy received by each patient. An autologous stem cell transplant, including mobilization chemotherapy, conditioning regimen, and any maintenance therapy, was counted as 1 line of therapy. Radiation therapy was counted as a line of therapy. Myeloma staging was conducted according to the International Uniform Response Criteria for Multiple Myeloma.

^†Response duration was from the time of first documentation of any response to the time of progression. For all patients, response was first documented 2 weeks after CAR-BCMA T-cell infusion.